BCM
ATOS icon

Bridgeway Capital Management’s Atossa Therapeutics ATOS Stock Holding History

Bridgeway Capital Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,747
Closed -$92K – 1313
2019
Q1 		$92K Buy
+1,747
New +$50.9K ﹤0.01% 1284

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
AIP
Ahrens Investment Partners Lafayette, Louisiana $202M AUM 3.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bridgeway Capital Management's ATOS Position: Q2 2019 in Review

Bridgeway Capital Management sold out of Atossa Therapeutics (ATOS) in Q2 2019, closing a stake of 1,747 shares — an estimated $92K sold.

Bridgeway Capital Management first reported a position in ATOS in Q1 2019 and held it in 1 quarter. The position peaked at $92K in Q1 2019. 14 funds tracked by Wall St. Rank hold ATOS as of Q2 2019.

  • Bridgeway Capital Management reported no remaining Atossa Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Bridgeway Capital Management sold 1,747 Atossa Therapeutics shares in Q2 2019, an estimated $92K.
  • Bridgeway Capital Management first reported a position in Atossa Therapeutics in Q1 2019 and held it in 1 quarter.
  • Bridgeway Capital Management's Atossa Therapeutics position peaked at $92K in Q1 2019.
  • 14 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.